Identification of Lynch Syndrome Carriers among Patients with Small Bowel Adenocarcinoma

Small bowel adenocarcinoma (SBA) is a rare disease which can be associated with Lynch syndrome (LS). LS tumors are characterized by the presence of microsatellite instability (MSI) and/or the loss of mismatch repair (MMR) protein expression. In SBA, the frequency of MMR deficient (MMRd) tumors varie...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers 2021-12, Vol.13 (24), p.6378
Hauptverfasser: Sánchez, Ariadna, Bujanda, Luis, Cuatrecasas, Miriam, Bofill, Alex, Alvarez-Urturi, Cristina, Hernandez, Goretti, Aguilera, Lara, Carballal, Sabela, Llach, Joan, Herrera-Pariente, Cristina, Iglesias, Mar, Rivero-Sánchez, Liseth, Jung, Gerhard, Moreno, Lorena, Ocaña, Teresa, Bayarri, Carolina, Pellise, Maria, Castells, Antoni, Castellví-Bel, Sergi, Balaguer, Francesc, Moreira, Leticia
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Small bowel adenocarcinoma (SBA) is a rare disease which can be associated with Lynch syndrome (LS). LS tumors are characterized by the presence of microsatellite instability (MSI) and/or the loss of mismatch repair (MMR) protein expression. In SBA, the frequency of MMR deficient (MMRd) tumors varies from 5% to 35%. This study aims to describe the prevalence of LS carriers among patients with MMRd small bowel adenocarcinomas. A multicenter retrospective study with identification and MMR testing of all consecutive SBA between 2004 and 2020 in a multicenter Spanish study. Demographical data, tumor characteristics, follow-up and survival information were collected. Germline testing was driven by identification of MMRd tumors. A total of 94 individuals diagnosed with SBA were recruited. We observed 20 (21.3%) MMRd tumors. In 9/15 (60%) patients with MMRd tumors, a pathogenic variant was identified (three MLH1, four MSH2, one MSH6 and one PMS2). Accordingly, the prevalence of LS among all SBA cases was 10.1%. More than one-fifth of SBA display MMRd and in more than a half is due to LS. Our data supports the implementation of universal MMR tumor testing among SBA for the identification of LS families.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers13246378